Adjuvant Comparison and Characterization of Peanut Antigen

花生抗原的佐剂比较和表征

• 批准号: 10892634
• 负责人: HERMAN STAATS
• 金额: $ 179.68万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10892634
• 关键词: Adaptive Immune System; Adjuvant; Allergens; Allergic Disease; Animal Model; Animals; Antigens; Autoimmune Diseases; Basic Science; Biological Assay; Cells; Collaborations; Communicable Diseases; Communities; Contractor; Data; Development; Disease; Disease Outcome; End Point Assay; Fingerprint; Future; Goals; Human; Immune; Immunity; Immunologics; In Vitro; Innate Immune Response; Ligands; Measures; National Institute of Allergy and Infectious Disease; Peptides; Protocols documentation; Side; Site; Standardization; TLR4 gene; TLR7 gene; Tissues; Vaccines; Work; adaptive immune response; clinically relevant; data management; in vivo; novel vaccines; pathogen; programs; research and development; vaccine development

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms and have potential for a given antigen and/or disease target. Contractors supported through the ACC program will be expected to: 1) collaborate with each other, including using standardized protocols or endpoint assays; 2) screen additional adjuvants at the direction of NIAID; and 3) share both positive and negative results in order to help guide basic research and vaccine development activities within the program and across the broader scientific community. In addition, data generated from ACC-supported studies will be made publicly available, enabling the rational selection of adjuvants and the future development of more effective vaccines against infectious diseases, and/or new vaccines to treat allergic or autoimmune diseases.

调整比较和表征（ACC）计划的目的是与临床相关的疫苗/抗原平台相结合的调节器的并排比较，并建立了针对特定机制的全身性和组织特异性免疫学特征（“免疫指纹”），以通过不同的机制来使用不同的机制，并且可以通过不同的机制来使用给定的替代品和/或/或/或疾病。通过ACC计划支持的承包商将有望：1）相互合作，包括使用标准化协议或端点分析； 2）在NIAID方向上屏幕额外的调节器； 3）分享积极和负面的结果，以帮助指导计划内以及整个更广泛的科学界的基础研究和疫苗开发活动。此外，将公开提供从ACC支持的研究产生的数据，从而使调节器的合理选择以及未来开发针对感染性疾病的更有效的疫苗，以及/或新的疫苗来治疗过敏或自身免疫性疾病。